[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 55, "title": "CEO, President & Executive Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 62, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 47, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 62, "title": "Chief Development Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.945, "open": 0.9677, "dayLow": 0.9555, "dayHigh": 0.9725, "regularMarketPreviousClose": 0.945, "regularMarketOpen": 0.9677, "regularMarketDayLow": 0.9555, "regularMarketDayHigh": 0.9725, "beta": 0.48, "forwardPE": -0.6837209, "volume": 9397, "regularMarketVolume": 9397, "averageVolume": 105615, "averageVolume10days": 24260, "averageDailyVolume10Day": 24260, "bid": 0.679, "ask": 1.24, "bidSize": 200, "askSize": 200, "marketCap": 25128408, "fiftyTwoWeekLow": 0.881, "fiftyTwoWeekHigh": 6.47, "priceToSalesTrailing12Months": 3.396649, "fiftyDayAverage": 1.16128, "twoHundredDayAverage": 1.812655, "currency": "USD", "enterpriseValue": -30409114, "floatShares": 12091772, "sharesOutstanding": 26298700, "sharesShort": 26439, "sharesShortPriorMonth": 2426, "sharesShortPreviousMonthDate": 1728950400, "dateShortInterest": 1731628800, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.28722, "heldPercentInstitutions": 0.31882998, "shortRatio": 0.41, "shortPercentOfFloat": 0.0016, "impliedSharesOutstanding": 27577100, "bookValue": 1.947, "priceToBook": 0.490755, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -24183000, "trailingEps": -1.01, "forwardEps": -1.94, "enterpriseToRevenue": -4.11, "enterpriseToEbitda": 1.131, "52WeekChange": -0.45058137, "SandP52WeekChange": 0.21027291, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LVTX", "underlyingSymbol": "LVTX", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "firstTradeDateEpochUtc": 1616765400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f272303e-4305-36b0-b7df-26c82acd7c44", "messageBoardId": "finmb_546792242", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.9555, "targetHighPrice": 2.954968, "targetLowPrice": 1.9696343, "targetMeanPrice": 2.3046167, "targetMedianPrice": 1.9892584, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 86800000, "totalCashPerShare": 3.301, "ebitda": -26883000, "totalDebt": 6163000, "quickRatio": 6.233, "currentRatio": 6.39, "totalRevenue": 7398000, "debtToEquity": 14.373, "revenuePerShare": 0.274, "returnOnAssets": -0.15991001, "returnOnEquity": -0.45299, "grossProfits": 7234000, "freeCashflow": -17983250, "operatingCashflow": -27081000, "grossMargins": 0.97783, "operatingMargins": -3.71479, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]